谁将受益于沃拉西登尼布? 从文献中审查数据和公开问题
Amélie Darlix1,2, Matthias Preusser3, Shawn L Hervey-Jumper4
1Department of Medical Oncology, Institut Régional du Cancer de Montpellier, University of Montpellier, Montpellier, France.
Neuro-oncology practice
|January 8, 2025
概括
异酸脱酶 (IDH) 抑制剂,如vorasidenib,对2级IDH突变性质瘤显示有前途,改善无进展的生存率. 需要进一步的研究,以解决在高度质瘤和其他治疗中最佳使用的问题.
科学领域:
- 神经瘤学神经瘤学
- 分子瘤学分子瘤学
- 临床神经学 临床神经学
背景情况:
- 异酸脱酶 (IDH) 抑制剂代表了IDH突变性 (mIDH) 质瘤的显著治疗进展.
- 传统的治疗方法,如放射和化疗,可以引起神经毒性影响,突出需要新的治疗策略.
- 在INDIGO研究中,Vorasidenib在改善2级mIDH质瘤患者无进展生存率方面的疗效得到了证实.
研究的目的:
- 审查目前关于IDH抑制剂用于mIDH结质瘤的数据.
- 解决关于治疗时间,在更高度质瘤中使用以及与其他模式集成的未解答问题.
- 为与患者讨论治疗缺口提供一个框架,并概述未来的研究需求.
主要方法:
- 审查现有的临床数据和关于IDH抑制剂在mIDH质瘤的文献.
- 分析INDIGO研究结果对2级mIDH质瘤中的vorasidenib.
- 讨论临床影响和未来的研究方向.
主要成果:
- 沃拉西迪尼布在2级mIDH结质瘤患者中改善了无进展的存活率.
- 这种药物一般耐受性很好,这表明它具有良好的安全性.
- 关于其用于更高度质瘤和最佳治疗顺序的重要问题仍然存在.
结论:
- IDH 抑制剂,以 vorasidenib 为例,为 mIDH 质瘤提供了一个有前途的新治疗途径.
- 进一步的临床研究至关重要,以优化这些药物的应用,跨不同的质瘤等级和治疗范式.
- 解决目前的知识差距对于完善mIDH质瘤患者的神经瘤治疗策略至关重要.
更多相关视频
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
1.7K
08:29Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
14.7K
相关概念视频
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
219
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
219
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:11Clinical Trials: Overview
2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
01:28Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K